Johnson & Johnson (JNJ) Stake Lowered by Boston Financial Mangement LLC

Boston Financial Mangement LLC cut its holdings in Johnson & Johnson (NYSE:JNJ) by 0.4% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 240,426 shares of the company’s stock after selling 968 shares during the quarter. Johnson & Johnson makes up 2.3% of Boston Financial Mangement LLC’s holdings, making the stock its 4th biggest holding. Boston Financial Mangement LLC’s holdings in Johnson & Johnson were worth $31,806,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Lenox Wealth Advisors Inc. boosted its stake in shares of Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Johnson & Johnson by 241.0% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after purchasing an additional 841 shares in the last quarter. Ullmann Financial Group Inc. acquired a new stake in shares of Johnson & Johnson during the first quarter valued at about $186,000. Taylor Wealth Management Partners boosted its stake in shares of Johnson & Johnson by 19.8% during the first quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock valued at $188,000 after purchasing an additional 250 shares in the last quarter. Finally, Puplava Financial Services Inc. acquired a new stake in shares of Johnson & Johnson during the second quarter valued at about $202,000. 66.06% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts have recently commented on JNJ shares. Credit Suisse Group set a $154.00 price target on Johnson & Johnson and gave the company an “outperform” rating in a research note on Thursday, October 19th. Royal Bank of Canada lifted their price objective on Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 18th. Atlantic Securities lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price objective on the stock. in a research note on Friday, July 21st. Jefferies Group LLC reaffirmed a “hold” rating and issued a $145.00 price objective (up from $140.00) on shares of Johnson & Johnson in a research note on Friday, July 14th. Finally, Citigroup Inc. started coverage on Johnson & Johnson in a research note on Monday, September 25th. They issued a “neutral” rating and a $140.00 price objective on the stock. Four analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $143.70.

ILLEGAL ACTIVITY WARNING: “Johnson & Johnson (JNJ) Stake Lowered by Boston Financial Mangement LLC” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/11/11/johnson-johnson-jnj-is-boston-financial-mangement-llcs-4th-largest-position.html.

Johnson & Johnson (NYSE JNJ) traded down $0.79 during mid-day trading on Friday, reaching $139.56. The company’s stock had a trading volume of 4,240,400 shares, compared to its average volume of 5,939,647. Johnson & Johnson has a twelve month low of $109.32 and a twelve month high of $144.35. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. The stock has a market capitalization of $377,053.09, a PE ratio of 19.66, a P/E/G ratio of 2.85 and a beta of 0.82.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The firm had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. During the same quarter in the prior year, the firm earned $1.68 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. equities research analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be paid a dividend of $0.84 per share. The ex-dividend date is Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.41%. Johnson & Johnson’s payout ratio is 58.33%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply